VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Lenalidomide (Primary) ; Pelareorep (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MUK eleven; VIRel
- 09 May 2017 Planned End Date changed from 1 May 2019 to 1 Oct 2020.
- 09 May 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019.
- 09 May 2017 Planned initiation date changed from 1 Feb 2017 to 30 May 2017.